Testosterone safety, efficacy data on Peyronie's treatment among sexual dysfunction research
April 17th 2014The safety of testosterone replacement therapy has been the subject of two recently published studies, which were followed by a January 2014 FDA announcement that the agency is investigating the risk of stroke, heart attack, and death in men taking TRT. Additional data on the safety of TRT, including its use in men following radical prostatectomy, will be presented at the AUA meeting, said John J. Mulcahy, MD, PhD.
Pediatric UTI marker, post-surgery antimicrobial prophylaxis among infection studies to watch for
April 17th 2014In discussing research at the 2014 AUA annual meeting, Anthony J. Schaeffer, MD, called attention to an important paper concerning urinary tract infection in children, as well as another study showing that antimicrobial prophylaxis after surgery is subject to considerable variation.
Stone research indicates URS over ESWL trend continuing
April 17th 2014At the 2012 AUA annual meeting, researchers reported that ureteroscopy had overtaken extracorporeal shock wave lithotripsy (ESWL) as the treatment of choice for kidney stones. Look for research at the 2014 meeting showing that trend is ongoing.
Laparoscopy/robotics studies explore the limits of minimally invasive surgery
April 17th 2014Urologists continue to push the limits of minimally invasive surgery, and key papers presented at the AUA meeting will explore the functional and cancer control outcomes associated with minimally invasive and robotic procedures in prostate cancer and renal cell carcinoma. When to use such approaches remains a source of controversy.
Advanced prostate cancer research focuses on newer agents for mCRPC
April 17th 2014Research in advanced prostate cancer is largely focused on newer agents for metastatic castration-resistant prostate cancer, including abiraterone acetate (ZYTIGA), enzalutamide (XTANDI), radium Ra 223 dichloride (Xofigo), and the immunotherapy sipuleucel-T (Provenge).
Infertility research explores linkage to all-cause mortality, psychiatric disorders
April 17th 2014A number of studies at the 2014 AUA annual meeting will indicate that male infertility is a harbinger of other diseases, specifically suggesting “linkage to all-cause mortality, psychiatric disorders, morbidity, and offspring birth defect risk,” said James M. Hotaling, MD, assistant professor of surgery in the division of urology at the University of Utah, Salt Lake City.
Updates to MAPP project top interstitial cystitis/bladder pain syndrome highlights
April 17th 2014The most informative presentations on interstitial cystitis/bladder syndrome at the 2014 AUA annual meeting will be a plenary talk by J. Quentin Clemens, MD, updating attendees on the National Institute of Diabetes and Digestive and Kidney Diseases’ Multidisciplinary Approach to Pelvic Pain project and an abstract providing long-term follow-up on the use of cyclosporine A in patients with refractory IC, according to Philip M. Hanno, MD, MPH.
Urology Product Preview April 2014
April 16th 2014Drugs and devices in the pipeline from Astellas Pharma, Medivation, Repros Therapeutics, Metamark Genetics, Argos Therapeutics, S1 Biopharma, Ipsen, Sprout Pharmaceuticals, Antigen Express, Generex Biotechnology, Veloxis Pharmaceuticals, and Absorption Pharmaceuticals.
Ophthalmologists update advisory on alpha-blockers
April 14th 2014The American Society of Cataract and Refractive Surgery and the American Academy of Ophthalmology have jointly issued an educational update about cataract surgery complications associated with systemic alpha-blockers based on the recent publication of two studies.
Surgical POP treatment rising among older women
April 11th 2014The number of older women being diagnosed with and treated for pelvic organ prolapse increased dramatically during the first decade of the 21st century, and surgical interventions gained in dominance. However, while mesh-based transvaginal repair seemed to gain early acceptance, its utilization was impacted by FDA safety notifications about serious mesh-related complications, reported researchers from Weill Cornell Medical College, New York.
Liposomal botulinum shows promise for refractory OAB
April 11th 2014Intravesical administration of a liquid liposomal formulation of onabotulinumtoxinA (“Liposomal BoNT-A,” Lipella Pharmaceuticals) shows promise as a safe and effective treatment for refractory overactive bladder (OAB), according to a pilot study presented at the European Association of Urology annual congress in Stockholm, Sweden.
Ideal bladder injury treatment modality unclear
April 10th 2014There has been a movement favoring noninvasive and minimally invasive approaches for management of urologic trauma cases, but findings from a multi-institutional retrospective study indicate that at least for patients with extraperitoneal bladder injury, evidence-based data are needed to justify that trend.
RT, hormonal combo treatment reduces prostate cancer mortality
April 10th 2014Adding local radiotherapy to hormonal treatment more than halves long-term prostate cancer-specific mortality and substantially decreases overall mortality in men with non-metastatic locally advanced or high-risk prostate cancer, according to an updated analysis of clinical trial data from the Scandinavian Prostate Cancer Group’s Study VII.
3-D mapping enhances accuracy of prostate biopsy
April 10th 2014Three-dimensional mapping biopsy (3DMB) of the prostate provides a more accurate disease assessment and in doing so may allow more confident decision making when patients and their physicians are trying to resolve issues surrounding observation or more aggressive therapies, a study from the University of Colorado School of Medicine, Denver, suggests.
‘Obesity paradox’ appears to fit for men with renal cell carcinoma
April 10th 2014A study from Memorial Sloan-Kettering Cancer Center, New York sheds light on the “obesity paradox” seen with renal cell carcinoma while at the same time demonstrating the emerging value of genomics in understanding cancer and other diseases.
Gene set breaks high-grade bladder cancer into two subtypes
April 10th 2014Researchers at the University of North Carolina School of Medicine, Chapel Hill, have identified a discrete set of genes that segregate high-grade bladder cancer into two distinct subtypes-basal-like and luminal-each of which appears to have its own molecular characteristics and outcome. The authors also found that the two subtypes share many of the characteristics seen in basal and luminal breast cancer subtypes, a discovery with clinical implications.
Dose-escalated IMRT appears safe in prostate cancer patients
April 7th 2014Dose-escalated intensity-modulated radiation therapy (IMRT) with use of a moderate hypofractionation regimen (72 Gy in 2.4-Gy fractions) can safely treat patients with localized prostate cancer with limited grade 2 or 3 late toxicity, according to a recently published study.
AUA Exhibit Hall Highlights: Orlando 2014
April 2nd 2014This guide features products and services from manufacturers that are exhibiting at the AUA annual meeting in Orlando. Exhibit hall booth numbers have been included so that you can search for product demonstrations and exhibits that are of particular interest to you.
SGR repeal and the 2014 Joint Advocacy Conference: Timing is everything
April 1st 2014The 2014 Urology Joint Advocacy Conference (JAC), co-sponsored by the American Association of Clinical Urologists and the American Urological Association, turned out to be an opportune time for urologists visiting Capitol Hill.
Orlando: Family-friendly fun and much more
April 1st 2014The AUA returns to Orlando-one of the nation’s most family-friendly, fun cities-for its 2014 annual meeting, May 16-21. Although this central Florida town is most frequently associated with a certain beloved mouse-and Disney’s many parks are well worth a visit, regardless of your age-there are plenty of other activities to make all ages smile.